

Media Release

Zofingen, 28 December 2020

Siegfried Successfully Issues Two Hybrid Convertible Bonds in the Amount of 80 Million Swiss Francs



As announced earlier, EGS Beteiligungen AG will participate in the financing of Siegfried's acquisition of two Novartis pharmaceutical production sites in Spain through two hybrid convertible bonds issued by Siegfried.

The bonds entitle EGS Beteiligungen AG to convert the principal amount of 80 million Swiss Francs in total within 5 years into shares of Siegfried Holding AG (SIX:SFZN) should certain conversion conditions be met. In case of a conversion, and including the shares already held by EGS Beteiligungen AG today, this would result in a stake in Siegfried's share capital of about 6.6 percent. The additionally required shares will come from treasury shares held by Siegfried already today. A capital increase is not planned in this context.

As of today, all conditions required for a formal closing of the transaction with Novartis have been met. A separate announcement concerning the closing of the transaction is expected to be issued in the first days of January 2021.

Siegfried

Contact

Media: Miriam Anton Head Corporate Communications miriam.anton@siegfried.ch Tel. +41 62 746 12 71 Mob. +41 79 366 32 73

Financial Analysts: Dr. Reto Suter Chief Financial Officer reto.suter@siegfried.ch Tel. +41 62 746 11 35

Siegfried Holding AG Untere Bruehlstrasse 4 CH-4800 Zofingen

This media release on the web:

www.siegfried.ch/media-releases

About Siegfried

The Siegfried Group is a global life sciences company with sites in Switzerland, the USA, Malta, China, Germany and France. In 2019, the company achieved sales of 833.5 million Swiss francs and currently employs about 2500 people at nine sites on three continents. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN).

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, and cartridges) for the pharmaceutical industry and provides development services.